|
A healthy 2019: Four paws for more relaxation and exercise
|
22 January 2019 |
|
Boehringer Ingelheim initiates a collaborative partnership with Science 37 to accelerate patient centricity in the development of novel therapies
|
08 January 2019 |
|
Boehringer Ingelheim inaugurates new centre for agile working methods
|
31 October 2018 |
|
Boehringer Ingelheim increases awareness of health with the micro enterprise project 'Elephants' in South India
|
15 October 2018 |
|
Global survey reveals that physicians need more information to assess the impact of treatment sequencing on patient survival in EGFR mutation-positive NSCLC
|
26 September 2018 |
|
New tablet production facility in Ingelheim: Centerpiece for global launches
|
03 September 2018 |
|
Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations and Oxford BioMedica announce new partnership to develop first-in-class gene therapy for cystic fibrosis
|
07 August 2018 |
|
Spiolto® Respimat® enables greater physical activity in people living with Chronic Obstructive Pulmonary Disease
|
23 May 2018 |
|
Boehringer Ingelheim R&D pushes to transcend disease boundaries
|
26 April 2018 |
|
Boehringer Ingelheim and Lilly announce an academic collaboration with University of Oxford
|
16 April 2018 |
|
Boehringer Ingelheim and OSE Immunotherapeutics announce global immuno-oncology partnership to develop a pioneering checkpoint inhibitor for the treatment of advanced solid tumors
|
05 April 2018 |
|
FDA grants Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease
|
19 March 2018 |
|
Inspirational patient stories reveal the challenging realities of living with devastating rare disease
|
27 February 2018 |
|
Boehringer Ingelheim marks great progress in immuno-oncology research partnerships in 2017
|
11 December 2017 |
|
Boehringer Ingelheim makes many of its best molecules openly available to the scientific community via opnMe.com to unlock their full potential
|
21 November 2017 |
|
Boehringer Ingelheim and MiNA Therapeutics to develop novel treatment approaches for fibrotic liver diseases
|
09 November 2017 |
|
Efficacy and safety maintained in patients who switched from Humira® to biosimilar Cyltezo®
|
06 November 2017 |
|
Boehringer Ingelheim expands collaboration with Sarah Cannon Research Institute to investigate novel immuno-oncology combination therapy
|
30 October 2017 |
|
IPF World Week 2017: Boehringer Ingelheim helps healthcare professionals to 'listen for the sounds of IPF'
|
19 September 2017 |
|
Boehringer Ingelheim Pharmaceuticals, Inc. receives FDA approval for CyltezoTM (adalimumab-adbm), a biosimilar to Humira®
|
04 September 2017 |